Examining Medicare Part D Medication Therapy Management program in the context of mental health

Published:December 21, 2019DOI:



      To describe and compare the delivery of medication therapy management (MTM) between Medicare beneficiaries with and without mental health conditions.


      Nationally representative cross-sectional study that used a 20% random sample of 2014 Medicare Parts A, B, and D data merged with a 100% sample of 2014 MTM data.

      Setting and participants

      Medicare beneficiaries continuously enrolled in Parts A, B, and D in 2014 were included in this study. Comprehensive medication review (CMR) use and MTM delivery were examined among a subset of 825,003 MTM-enrolled beneficiaries.

      Outcome measures

      Predisposing, enabling, and need characteristics were selected on the basis of the Andersen Behavioral Model of Health Services Use. Descriptive, bivariable, and multivariable logistic regression statistics were used to determine associations between beneficiary characteristics and MTM delivery.


      A total of 3,016,620 (43%) and 3,997,105 beneficiaries (57%) were categorized into mental health and nonmental health cohorts, respectively. MTM enrollment in the mental health cohort was significantly higher than that in the nonmental health cohort (17.4% vs. 7.5%, P < 0.001). However, once enrolled, a greater proportion of beneficiaries in the nonmental health cohort received CMRs (19.3% vs. 17.7%, P < 0.001). Patients in the mental health cohort were more likely to have hospitalization (22% vs. 9.2%, P < 0.001) or emergency department visit (25.2% vs. 11.5%, P < 0.001) and used more medications in 2014 (16 % vs. 12%, P < 0.001). The proportion of patients in the mental health cohort receiving a CMR in 2014 that had at least 1 medication-related problem (MRP) identified and resolved was higher than that of patients in the nonmental health cohort (24.8% vs. 20.6%, P < 0.001).


      Although patients with mental health conditions are more often enrolled into MTM, they are less likely to receive a CMR once enrolled. Given that this population has higher medical complexity and a higher MRP burden following a CMR, opportunities exist for pharmacists to enhance MTM delivery in this population.
      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • National Institute of Mental Health
        Mental illness.
        (Available at:)
        • Murray C.J.
        • Atkinson C.
        • Bhalla K.
        • et al.
        The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.
        JAMA. 2013; 310: 591-608
        • Correll C.U.
        Balancing efficacy and safety in treatment with antipsychotics.
        CNS Spectr. 2007; 12: 12-20.35
        • Weber N.S.
        • Cowan D.N.
        • Millikan A.M.
        • Niebuhr D.W.
        Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital discharge survey.
        Psychiatr Serv. 2009; 60: 1059-1067
        • Weber N.S.
        • Fisher J.A.
        • Cowan D.N.
        • Niebuhr D.W.
        Psychiatric and general medical conditions comorbid with bipolar disorder in the national hospital discharge survey.
        Psychiatr Serv. 2011; 62: 1152-1158
        • De Hert M.
        • Correll C.U.
        • Bobes J.
        • et al.
        Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.
        World Psychiatry. 2011; 10: 52-77
        • Walker E.R.
        • Mcgee R.E.
        • Druss B.G.
        Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis.
        JAMA Psychiatry. 2015; 72: 334-341
        • Tallian K.B.
        • Hirsch J.D.
        • Kuo G.M.
        • et al.
        Development of a pharmacist-psychiatrist collaborative medication therapy management clinic.
        J Am Pharm Assoc (2003). 2012; 52: e252-e258
        • Haddad P.M.
        • Brain C.
        • Scott J.
        Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.
        Patient Relat Outcome Meas. 2014; 5: 43-62
        • Cobb C.D.
        Optimizing medication use with a pharmacist-provided comprehensive medication management service for patients with psychiatric disorders.
        Pharmacotherapy. 2014; 34: 1336-1340
        • Medford-Davis L.N.
        • Shah R.
        • Kennedy D.
        • Becker E.
        The role of mental health disease in potentially preventable hospitalizations: findings from a large state.
        Med Care. 2018; 56: 31-38
        • Ng S.
        • Jones R.B.
        • Schwartzwald L.
        • et al.
        Innovative partnership between a rural mental health center and community pharmacy: integration of a mental health pharmacist.
        Innov Pharm. 2019; 10: 17
        • Phatak A.
        • Prusi R.
        • Ward B.
        • et al.
        Impact of pharmacist involvement in the transitional care of high-risk patients through medication reconciliation, medication education, and postdischarge call-backs (IPITCH Study).
        J Hosp Med. 2016; 11: 39-44
        • Silvia R.J.
        Utilization of a psychiatric clinical pharmacist in an integrated behavioral health program of a community health center.
        Ment Health Clin. 2014; 4: 287-291
        • Gable K.N.
        • Williams K.E.
        Assertive community treatment and psychiatric pharmacy.
        Ment Health Clin. 2013; 2: 243-245
        • Rubio-Valera M.
        • Chen T.F.
        • O’Reilly C.L.
        New roles for pharmacists in community mental health care: a narrative review.
        Int J Environ Res Public Health. 2014; 11: 10967-10990
        • Finley P.R.
        • Crismon M.L.
        • Rush A.J.
        Evaluating the impact of pharmacists in mental health: a systematic review.
        Pharmacotherapy. 2003; 23: 1634-1644
        • Lynum K.S.
        • Hill A.M.
        Psychiatric services: a platform for MTM.
        J Pharm Pract. 2015; 28: 13-20
        • American Psychological Association Service Inc
        Enact the Medicare mental health access act to improve patient access to psychologists' services.
        (Available at:)
        • Wang P.S.
        • Lane M.
        • Olfson M.
        • Pincus H.A.
        • Wells K.B.
        • Kessler R.C.
        Twelve-month use of mental health services in the United States: results from the national comorbidity survey replication.
        Arch Gen Psychiatry. 2005; 62: 629-640
        • Research Data Assistance Center
        Part D Medication Therapy Management Data file.
        (Available at:)
        • Aday L.A.
        • Andersen R.
        A framework for the study of access to medical care.
        Health Serv Res. 1974; 9: 208-220
        • Andersen R.
        • Newman J.F.
        Societal and individual determinants of medical care utilization in the United States.
        Milbank Mem Fund Q Health Soc. 1973; 51: 95-124
        • Wang J.
        • Qiao Y.
        • Shih Y.C.T.
        • et al.
        PHS165. The implementation of Medicare Part D and the health implications of medication therapy management eligibility criteria.
        Value Health. 2014; 17: A153
        • Stuart B.
        • Hendrick F.B.
        • Shen X.
        • et al.
        Eligibility for and enrollment in Medicare Part D Medication Therapy Management Programs varies by plan sponsor.
        Health Aff (Millwood). 2016; 35: 1572-1580
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Snyder M.E.
        • Frail C.K.
        • Jaynes H.
        • Pater K.S.
        • Zillich A.J.
        Predictors of medication-related problems among medicaid patients participating in a pharmacist-provided telephonic medication therapy management program.
        Pharmacotherapy. 2014; 34: 1022-1032
        • Watkins A.
        • McKee J.
        • Hughes C.
        • Pfeiffenberger T.
        Community pharmacists’ attitudes toward providing care and services to patients with severe and persistent mental illness.
        J Am Pharm Assoc (2003). 2017; 57 (S217.e2–S224.e2)
        • Peterson-KFF Health System Tracker
        What are the current costs and outcomes related to mental health and substance use disorders?.
        (Available at:)
        • Doucette W.R.
        • Zhang Y.
        • Chrischilles E.A.
        • et al.
        Factors affecting Medicare Part D beneficiaries’ decision to receive comprehensive medication reviews.
        J Am Pharm Assoc (2003). 2013; 53: 482-487
        • Substance Abuse and Mental Health Services Administration
        Racial/Ethnic Differences in Mental Health Service Use among Adults. HHS Publication No. SMA-15-4906.
        Substance Abuse and Mental Health Services Administration, Rockville, MD2015
        • Brown P.
        • Calnan M.
        • Scrivener A.
        • Szmukler G.
        Trust in mental health services: a neglected concept.
        J Ment Health. 2009; 18: 449-458
        • Angermeyer M.C.
        • Matschinger H.
        Labeling—stereotype--discrimination. An investigation of the stigma process.
        Soc Psychiatry Psychiatr Epidemiol. 2005; 40: 391-395
        • Greene J.A.
        • Bina R.
        • Gum A.M.
        Interventions to increase retention in mental health services: a systematic review.
        Psychiatr Serv. 2016; 67: 485-495


      Meena N. Murugappan, PharmD, MPH, Research Associate and PhD Student, Social & Administrative Pharmacy, University of Minnesota College of Pharmacy, Minneapolis, MN


      Randall D. Seifert, PharmD, Professor, Associate Dean for Student and Professional Affairs, and Co-Director for Center for Leading Healthcare Change, University of Minnesota College of Pharmacy, Minneapolis, MN


      Joel F. Farley, PhD, FAPhA, Professor and Peters Endowed Chair in Pharmacy Practice Innovation, Department of Pharmaceutical Care and Health Systems, University of Minnesota College of Pharmacy, Minneapolis, MN